**Title: Pfizer Korea’s Vaccine Division Prioritizes Promoting Vaccination for a Healthier Future**
*(Subheading) A Focus on Prevention in the Changing Medical Landscape*
In today’s medical landscape, there is a growing emphasis on prevention rather than treatment, underscoring the importance of vaccines. With the advent of the COVID-19 pandemic, the awareness surrounding vaccinations has soared, leading to an increase in immunization efforts beyond the National Immunization Program (NIP). However, alongside this positive trend, there are also barriers such as vaccine hesitancy due to concerns about repeated vaccinations. Consequently, effective marketing strategies are crucial. Pfizer Korea’s Vaccine Division is spearheading efforts to raise awareness of preventable diseases, particularly through their flagship product, Prevenar 13. Leading this campaign are Deputy General Manager Jeong Seong-soo and Manager Kim Ye-bin, who oversee the adult and pediatric sectors, respectively.
*(Subheading) Pfizer’s Shifting Focus to Prevnar 13*
While Pfizer’s Vaccine Division previously dedicated its resources to developing a COVID-19 vaccine, the division has now shifted its focus to Prevenar 13. Representing a significant portion of the company’s vaccine portfolio, Prevenar 13 has become the top-selling pneumococcal vaccine for 13 consecutive years. Although the vaccine falls under the Prevenar 13 product range, it is crucial to differentiate between the roles of the two managers, as their target demographics and concerns vary due to differences in access to national vaccination programs.
*(Subheading) Promoting Adult Vaccination for a Healthy Aging Population*
Deputy General Manager Jeong Seong-soo, responsible for the Prevenar 13 adult team, highlights the importance of promoting adult vaccination as a means to achieve longevity in an aging society. He emphasizes the severity of pneumonia as the country’s third-leading cause of death and foremost respiratory disease. “We are striving to raise awareness of the seriousness of this condition and to underscore the pivotal role that pneumococcal vaccination plays in preventing it,” Deputy Director Jeong explains. However, incorporating the pediatric indication for Prevenar 13 into the NIP, which provides free vaccines, remains uncertain, posing financial barriers for adult vaccination. To overcome this challenge, Deputy Director Jeong aims to effectively communicate the importance and necessity of pneumococcal vaccination to both the public and medical professionals.
*(Subheading) Broadening Pediatric Awareness through NIP*
Simultaneously, Manager Kim Ye-bin, in charge of the Prevenar 13 pediatric team, is focusing on raising awareness through various channels, including YouTube, advertisements, and baby fairs. The team is actively targeting not only medical professionals but also parents, aiming to provide easy access to information regarding the pneumococcal vaccine. With over 10 years of real-world evidence through the National Immunization Program, the pediatric team relies on data summarizing the epidemiological impact of Prevenar 13 vaccination, particularly on serotype 3. Manager Kim notes the declining birth rate as a concern affecting the pediatric market, highlighting the need for discussions and innovative strategies to overcome this challenge.
*(Subheading) Collaborating for Family Vaccination*
Although the adult and pediatric teams focus on different demographic groups, they collaborate on the concept of family vaccination. Manager Kim explains that while pediatric sales surpass adult sales, collaboration with the adult team elevates support for family vaccinations in the pediatric market. As individuals age, reaching the recommended age of 65 for pneumococcal vaccination becomes increasingly crucial. Consequently, the importance of vaccinating adults is expected to grow, and the two teams aim to create a strong brand value that seamlessly transitions from pediatric to adult vaccination campaigns.
*(Subheading) Youthful Drive Fuels Pfizer’s Vaccine Division*
The Vaccine Division at Pfizer Korea is known for its dynamic energy, attributed to its relatively young workforce. Focusing on a single product, rather than juggling multiple offerings, allows the team to work passionately and serve as a driving force within the company. Leveraging their efforts, the Vaccine Division strives to increase pneumococcal pneumonia vaccination rates, ultimately contributing to a healthier population.
In conclusion, Pfizer Korea’s Vaccine Division is committed to promoting the value of preventive vaccination throughout all stages of life. Through targeted awareness campaigns and collaboration between the adult and pediatric teams, the division aims to provide a healthier future for individuals of all ages.
“The Vaccine Business Department works closely together as a team that strives to have a healthy life of all ages, from children to adults. We work with a sense of mission and aim to promote the value of vaccine prevention at the age of 100. . “
As the latest medical trend emphasizes prevention over treatment, the importance of vaccines is also emphasized. In particular, starting with the COVID-19 pandemic, vaccinations other than National Immunization (NIP) were actively carried out, which was an opportunity to raise awareness of vaccination.
However, on the contrary, since positive and negative factors intersect, such as reluctance to get vaccines due to repeated vaccinations such as the 1st and 2nd, it is important to know how to incorporate them into marketing.
In this situation, the vaccine division of Pfizer Korea is making efforts to raise awareness of the disease, focusing on Prevenar 13. The activities to publicize the importance of pneumococcal vaccination were emphasized through the Deputy General Manager Jeong Seong-soo and the Manager Kim Ye-bin, who is in charge of adult and pediatric areas, respectively.
Pfizer Adult Pediatric Vaccines Division Same strategy but different
Previously, Pfizer’s Vaccine Business Division worked together on the Corona 19 vaccine, but with the recent establishment of the COVID Division, it is focusing on Prevnar 13.
In other words, the scale is large enough to represent the vaccine division = Prevenar 13. In fact, Prevenar 13 has reached the milestone of being the top selling pneumococcal vaccine for 13 consecutive years.
Although they are grouped into a product group called Prevenar 13, the roles of the two PMs are divided into children and adults. In particular, their concerns and methods are different as their access to national vaccination as different as the age difference between the vaccination. subjects.
(From left) Pfizer Vaccine Division Manager Kim Ye-bin and Deputy General Manager Jeong Seong-soo
First of all, Deputy General Manager Jeong Seong-soo, who is in charge of the Prevenar 13 adult team, emphasized that Korea is focusing on promoting the need for adult vaccination as one of the options for a healthy life aged 100 years in the middle. an aging society.
“Pneumonia is a disease that everyone is familiar with, but it is a very serious disease that ranks 3rd in the country’s cause of death and 1st in respiratory disease from 2021,” said Deputy Director Jeong. “We are trying to publicize the seriousness and ultimately convey that the pneumococcal vaccine is an extremely important vaccine that can help.”
However, as mentioned above, if the pediatric indication for Prevenar 13 is included in the NIP, it is still unclear whether it will be introduced in adults. In other words, there are barriers because the vaccination target has to pay direct expenses rather than government support.
Deputy Director Jeong said, “If a vaccine is recommended, it may seem like it is for profit rather than for the health of patients, so I believe that not only ordinary users but also medical staff will be hesitant to vaccinate.” “The importance and need for pneumococcal vaccination We focus on delivering the message effectively to consumers,” he said.
In addition to this, he explains that he presents a message which focuses on the evidence that the pneumonia death rate increases from the age of 50.
Deputy Director Jeong said, “Unlike the previous pneumococcal vaccine, which was limited to people over the age of 65, we are approaching a direction that can expand the vaccination target based on data showing that the rate of pneumonia deaths increase with age. aged 50 or over.”
In addition, he said, “In Korea, a 23-valent polysaccharide vaccine is included in GI), but the focus is on invasive pneumococcal disease (IPD) such as meningitis and sepsis.” If Prevenar 13 is introduced to NIP because it has not been proven, I think it will actually help prevent pneumonia,” he stressed.
Indications for Prevenar 13
In fact, in 2021, domestic researchers evaluated the effects of a 13-valent protein conjugate vaccine, a 23-valent polysaccharide vaccine, and sequential vaccination of the two vaccines. -a protein-valent conjugate vaccine showed 66.4% and the 23-valent polysaccharide vaccine showed 18.5% efficacy.
Prevenar 13 with Emphasis on NIP Pediatric Awareness Strategies
While Prevenar 13’s adult team is focused on expanding its scope and expanding its role, Prevenar 13’s pediatric team, which has already joined the NIP, continues its efforts to raise awareness.
Manager Yebin Kim
Manager Kim Ye-bin, who is in charge of Prevenar 13’s pediatric team, said, “The vaccine is a consumer promotional item (CPC), and we conduct various marketing campaigns such as YouTube, advertisements, and baby fairs not not only for medical staff but also for general users such as mothers.” We are trying to raise awareness through different channels so that parents can have easy access to information related to the pneumococcal vaccine.”
In particular, in the case of children, it has a lot of real world evidence (RWE) over a period of 10 years since its release through NIP, etc.
Manager Kim said, “Through different channels, we deliver many messages to mainly medical staff with data summarizing the epidemiological changes during Prevenar 13 vaccination.” Serotype 3, which is clearly seen, is rarely seen in infants, which may be hypothesized to be due to the effect of the Prevnar 13 vaccination on infants and young children.”
Although they are grouped under the same product group called Prevenar 13, in terms of sales, the pediatric area included in NIP is more prominent.
However, apart from this, in the case of the children’s market, there are concerns about long-term measures due to the decrease in the birth rate.
He said, “In the pediatric market, a decrease in the birth rate leads to a decrease in sales, so I hope that a forum will be prepared to discuss different ways to overcome the birth rate as the biggest discussion topic in the future.”
In the end, the Prevenar 13 team is divided into adults and children, and the two PMs explain that although they think about the present, discussions are held to create synergies together in the future. The collaborative direction that comes out as part of these concerns is ‘family vaccination’.
Jeong Seong-soo, deputy general manager
Manager Kim said, “In some cases, the symposium is divided into children and adults, but at the same time, we collaborate with the adult team on the theme of family vaccination.”
Next, Deputy Director Jeong said, “Sales in the pediatric market are higher than those in adults, and we receive support by collaborating with family vaccinations in the pediatric market. “Since he is expected to reach the age of 65, I’ n think that the importance of vaccinating adults will increase even more.”
From a long-term perspective, they are trying to create brand value that continues from the activities of the pediatric team until they become eligible to be vaccinated for adults.
The Pfizer Vaccine Division seen by the two PMs is an organization where young blood flows hot. It means we focus on the UN team which is based on our youth compared to other departments.
Deputy General Manager Jung and Manager Kim said, “The Vaccine Business Department is very young compared to other departments, so we focus on one product, rather than several products, so we work passionately. ” We do this, serving as all. other driving force, and based on the efforts made by the Vaccine Business Department, we will strive to increase vaccination against pneumococcal pneumonia.”
#Vaccine #Business #Department #work #sense #duty #promote #prevention
